Xalkori (crizotinib) — Medica
Non-Small Cell Lung Cancer with Mesenchymal Epithelial Transition (MET) Mutation
Initial criteria
- age ≥ 18 years
- EITHER non-small cell lung cancer with high level MET amplification OR non-small cell lung cancer with MET exon 14 skipping mutation
Approval duration
1 year